Background: The effectiveness of combination therapy of transarterial chemoembolization and sorafenib for unresectable hepatocellular carcinoma are controversial in some studies. This metaanalysis aims to compare efficacy and safety, as well as regional disparities, between transarterial chemoembolization plus sorafenib and transarterial chemotherapy alone for hepatocellular carcinoma. Methods: We systematically searched multiple databases to select eligible studies. Studies comparing transarterial chemoembolization plus sorafenib and transarterial chemoembolization alone for unresectable hepatocellular carcinoma were included. Results: Thirteen studies including five randomized clinical trials with 2538 patients (1121 in combination therapy group and 1417 in monotherapy group) were selected. The combination therapy significantly improved time to progression (hazard ratio 0.66; 95% confidence interval 0.48-0.89; P = 0.006) and overall survival (hazard ratio 0.57; 95% confidence interval 0.45-0.72; P < 0.001) in Asian region but not in non-Asian countries (overall survival: hazard ratio 0.96, 95% confidence interval 0.73-1.20; time to progression: hazard ratio 1.08, 95% confidence interval 0.73-1.60). Additionally, disease control rate also favored combination therapy (hazard ratio 1.30; 95% confidence interval 1.00-1.69; P = 0.05), which simultaneously caused higher incidences of adverse events, including hand-foot skin reaction (relative ratio 7.03; 95% confidence interval 4.77-10.37), hematological events (relative ratio 3.14; 95% confidence interval 0.99-10.01), diarrhea (relative ratio 2.75; 95% confidence interval 1.74-4.35), hypertension (relative ratio 2.58; 95% confidence interval 1.33-4.99), rash (relative ratio 2.87; 95% confidence interval 1.86-4.43) and alopecia (relative ratio 4.88; 95% confidence interval 1.67-14.13). Conclusions: The combination of transarterial chemoembolizaiton and sorafenib significantly improves outcomes of unresectable hepatocellular carcinoma compared with transarterial chemoembolization monotherapy, especially in Asian region.
Introduction
Hepatocellular carcinoma (HCC) has become the most common primary malignancy of the liver, the sixth most common cancer and the second leading cause of death from cancer across the world (1). The incidence rates are highest in Eastern Asia and sub-Saharan Africa (2) . In most circumstances, HCC patients could be classified into five stages (0, A, B, C and D) on the basis of several prognostic and treatment-related variables such as tumor status and liver function according to the Barcelona Clinic Liver Cancer (BCLC) staging system under the guidelines of the European Association for the Study of the Liver (EASL) (3) . Currently, the curative treatment options against HCC include surgical resection, liver transplantation and local ablation in selected HCC patients in early cancer stages (4, 5) . However, obscure initiation of HCC often leads to a high rate of intermediated (stage B), advanced (stage C) or even metastatic (stage D) disease, when the curative treatments could not be applicable. In this circumstance, adjuvant therapy aiming to increase the survival after diagnosis becomes an important component in the management of unresectable HCC (3, 6, 7) . Transarterial chemoembolization (TACE) is recommended as the first-line therapy in the treatment of intermediated HCC (BCLC stage B) with robust evidence (3, 8, 9) , while sorafenib is the recommended treatment for advanced stage HCC. However, there is currently no consensus regarding a common treatment strategy for patients with advanced HCC (9, 10) . Finally, at the end stage (BCLC D), symptomatic treatment remains the best option (9) .
TACE refers to periodic injection of chemotherapeutic agents, mixed with embolic material, administered selectively into the feeding arteries of the tumor to obtain higher intra-tumor chemotherapeutic concentrations, while occlusion of blood flow also contributes to the tumor necrosis (11) . As a hypervascular tumor receiving majority of blood supply from the hepatic artery, HCC is therefore reasonably sensitive to the TACE treatment. Of note, TACE is still facing a bunch of challenges and problems. The longterm outcomes of patients treated with TACE are not fully satisfactory, with up to 80% of patients eventually presenting tumor progression, recurrence or even metastasis (12, 13) . The widely accepted explanation for this phenomenon is that embolization-induced hypoxia might stimulate protumoral pathways such as vascular endothelial growth factor (VEGF), promoting angiogenesis and thus growth of residual tumor cells (14, 15) .
Sorafenib, an oral multityrosine kinase inhibitor, is one of the few targeted molecular agents approved in systemic therapy against HCC, based on the results of two large double-blind, placebocontrolled, randomized, multicenter trials, demonstrating a median survival benefit of 2-3 months (12, 16, 17) . Sorafenib featuring antiangiogenic properties and direct antitumoral ability, by pharmacologically interacting with VEGF receptor 2 (VEGFR-2), plateletderived growth factor receptor (PDGFR) and the Ras/mitogen-activated protein kinase (MAPK) signaling pathway, might reverse the concurrent angiogenic effect of TACE administration (18) . The combination of TACE and sorafenib for unresectable HCC is therefore based on a strong mechanistic rationale that synergistic inhibition of revascularization and tumor proliferation improves the outcomes and prognosis. In recent years, the combination therapy of TACE and sorafenib has been increasingly used in patients with unresectable HCCs. Several clinical researches, including the randomized phase III trials, SPACE and TACE 2, were conducted to evaluate the effectiveness and safety of the combination therapy (19, 20) . However, the results of the current evidence are controversial, and the benefits of combination therapy have not been determined yet. The purpose of this meta-analysis is to review the current available evidences, to compare the efficacy and safety of the combination of TACE plus sorafenib with TACE therapy alone in the treatment for unresectable HCC.
Materials and methods

Search strategy
We performed a systematic literature search in three electronic databases: PubMed, EMBASE and Cochrane Library up to September 2017. The following searching strategy was applied: ('Nexavar' OR 'sorafenib' OR 'Raf 1 Kinase Inhibitor II') AND ('chemoemboli*' OR 'emboli*' OR 'TACE' OR 'transcatheter' OR 'transarterial') AND (((liver OR hepatic OR hepatocellular) AND (carcinom* OR cancer OR neoplasm* OR malign* OR tumor)) OR 'HCC' OR 'hepatoma*'). The references of all studies and meta-analysis were also manually scanned in order to retrieve potentially missing studies. This meta-analysis was designed, conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines (21) .
Selection criteria
Two independent authors (P.J. and S.S.) carefully scrutinized the titles and abstracts of the literatures from the initial search. Duplicated studies were first excluded. Then full texts of potential qualified studies were reviewed for a second screen. The inclusion criteria for our meta-analysis were as follows: (i) studies were randomized clinical trials (RCTs), as well as retrospective or prospective cohort or case-control studies; (ii) only publications with full texts in English were taken into consideration; (iii) searches were limited to human studies; (iv) evaluated TACE plus sorafenib and TACE alone for the treatment of diagnosed unresectable HCC; (v) participants were 18 years of age or older; (vi) primary endpoints included time to progression (TTP), or overall survival (OS), hazard ratio (HR), and its corresponding 95% confidence interval (CI) were available or could be calculated; (vii) reported adverse events among patients receiving sorafenib as secondary endpoints; (viii) data of objective response rate (ORR) and disease control rate (DCR) could be extracted; (ix) for studies reporting duplicated or overlapping RCTs and non-RCTs, only the most complete studies were included. Studies were excluded if they meet the following criteria: (i) studies were not original studies such as conference abstracts, reviews, expert opinions, editorials or case reports; (ii) patients diagnosed with another severe liver disease or other types of malignant tumors, heart failure, renal failure, human immunodeficiency virus infection.
Data extraction and quality assessment
Data extraction was conducted. The following data were extracted: (i) general information, including article title, first author, year of publication; (ii) study characteristics, including research methods, country of origin, study design, inclusion and exclusion criteria, number of patients and demographic variables, follow-up duration; (iii) endpoints measures, including HR and its corresponding 95% CI of TTP and OS, data of DCR and ORR, and adverse events among sorafenib users, including hand and foot skin reactions (HFSR), hematological events, diarrhea, hypertension, rash, fatigue and alopecia.
Quality assessment was performed by two investigators independently (P.J. and S.S.) and consensus was reached on all items through detailed discussion. As for RCT studies, quality assessment was performed based on Jadad scoring system, which graded the quality of a study from 0 (lowest) to 5 (highest), depending on randomization of allocation, sufficient blinding for allocation and intervention, and evaluation of loss to follow-up or exit status. While all included non-RCT studies were scored according to the NewcastleOttawa scale (22) , the scores ranged from zero to nine stars: four for selection, two for comparability and three for outcomes. In the current analysis, we considered a study rated seven or more stars in the Newcastle-Ottawa scale as a high-quality study.
Statistical analysis
Effect size for the primary endpoints was evaluated based on the HRs and their corresponding 95% CI of TTP and OS extracted from each included study. Effect size for the secondary endpoints was evaluated as the relative ratios (RRs) and 95% CI based on the incidences of the various adverse events reported. The significance of the pooled HRs and RRs was determined by z test (P < 0.05 was considered to be significant). Forest plots were constructed to represent the results of the risk analyses.
Either a fixed-or random-effect model was adopted to pool the study-specific HRs (RRs), according to the extent of heterogeneity. Heterogeneity across the studies was checked by χ 2 test and I 2 test. I 2 test quantifies the proportion of total variation across studies due to heterogeneity rather than chance. I 2 > 50% together with P < 0.10 indicated significant heterogeneity and suggested use of the random-effect model. Otherwise, a fixed-model was applied. Sensitivity analyses were performed to examine the impact of single study on pooled results via the leave-one-out approach to validate the stability of our outcomes. Funnel plots, Begg's rank correlation test and Egger's regression test were adopted to estimate the potential publication bias, and P > 0.05 indicated no statistically significant asymmetry for the latter two strategies (23) . Plus, subgroup analyses were conducted by region and research type. All meta-analyses were conducted using Stata 13.0 software (StatCorp, College Station, TX).
Results
Study selection
The initial search in PubMed, EMBASE and Cochrane Library electronic databases yielded a total of 3112 articles (Fig. 1) . After the removal of 391 duplicates, the remaining 2721 articles were scanned by titles and abstracts, and a total of 52 articles were selected for a full-text screening. Thirty-nine studies were excluded, among which 17 were conference abstracts, 14 did not provide sufficient data, 2 included overlapping information and 6 were metaanalyses. Finally, 13 studies were included in our meta-analysis (19, 20, (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) .
Study characteristics
The features of the 13 studies are listed in Table 1 . The published time period ranged from 2011 to 2017. Among them, five were multicenter or single-center RCTs, while the others were retrospective or prospective cohort studies and case-control studies. The 13 studies included 2538 patients with unresectable HCC, among which 1121 patients were treated with TACE combined with sorafenib, while 1417 patients in the control group received TACE with placebo or TACE alone. The included studies were conducted in several regions, namely, China, UK, USA, Germany, Italy, Japan, South Korea, Spain, Taiwan and France. The various studies used different methods of allocation to the experimental and control groups. The most common BCLC stages were B (intermediated stage) and C (advanced stage) with Child-Pugh class A or B, and most patients had an ECOG PS score of 0-1. The baseline characteristics in most non-RCT studies, such as BCLC stage, ECOG PS, AFP level, Child-Pugh class, MELD score and age, did not differ significantly between the TACE group and TACE plus sorafenib group, suggesting no obvious patient selection bias (Supplementary data, Table S1 ).
The chemoembolization and sorafenib treatment varied across the 13 studies (Table 2 ). Most studies chose epirubicin, cisplatin, doxorubicin, mitomycin, lobaplatin or hydroxycamptothecin as chemotherapeutics and used gelatin sponge, lipodol or certain types of beads for embolization. The dosage of sorafenib was 400 mg twice a day initially in nine studies, 400 mg once daily in one study (29) and 200 mg twice daily and increased to 400 mg twice a day in one study (30) . All studies allowed the dosage to be reduced in case of drug-related toxicity.
The assessed quality varied among the included studies. The quality assessments of the included RCTs using the Jadad score showed that each RCT study was awarded a score of more than 4 and thus considered to be a high-quality study (Table 3) . Notably, blinding and randomization were determined to be adequate in the five selected RCTs, whereas only two of these studies adequately described allocation concealment (19, 31) . Meanwhile, the quality assessment of the cohort or case-control studies using the Newcastle-Ottawa scale demonstrated that most data in non-RCT studies were considered of high quality with an evaluated score of 7 to 9 (Table 4) . However, the study by Huang et al. only received a score of 5 because of possible selection bias with unexplained participant dropout and insufficient follow-up.
Clinical outcomes
Overall survival Eleven studies (three RCTs, eight non-RCTs) provided information of the OS for the experimental and control groups, including the point estimate (HR) and its 95% CI (Fig. 2a) . The combined HR was 0.61 (95% CI 0.49-0.77, z = 4.29, P < 0.001), which indicated a significantly higher OS in the TACE plus sorafenib group rather than the TACE monotherapy group. Interestingly, the meta-analysis of RCTs suggested that there was no statistical difference between groups (HR = 0.94, 95% CI 0.76-1.16, z = 0.57, P = 0.567; Fig. 2b ). But the pooled HR of the cohort and case-control studies still favored the combination group with HR = 0.53 (95% CI 0.42-0.67, z = 5.27, P < 0.001; Fig. 2c ). Due to significant heterogeneity in the OS data (I 2 = 66.9%, P = 0.001), we chose the random-effect model for analysis. Begg's funnel plot and Egger's linear regression test were conducted to evaluate publication bias, which showed no evident asymmetry with P Begg = 0.436 (Supplementary data, Fig. S1a ), as Egger's test either suggested no publication bias (P Egger = 0.207). Sequential omission of each individual study showed a result pattern which was not changed by removing single study each time (Supplementary data, Fig. S1b ).
Time to progression
Seven studies (five RCTs and two non-RCTs) reported the required information for TTP comparison between groups. The overall HR of TTP was 0.80 (95% CI 0.62-1.05; z = 1.61; P = 0.108), suggesting much, though not significantly, lower risk of disease progression in the combination treatment group comparing to the monotherapy group (Fig. 3a) . Furthermore, the combined HR was 0.89 (95% CI 0.77-1.03; z = 1.51; P = 0.132) for RCTs ( Fig. 3b) and 0.53 (95% CI 0.41-0.69; z = 4.75; P < 0.001) for non-RCT studies (Fig. 3c) ; specifically, the latter analysis favored combination therapy. Significant heterogeneity exists in the TTP data as well (I 2 = 71.0%, P = 0.002), indicating the use of the random-effect model. Begg's funnel plots were symmetrical, showing no significant publication bias (P Begg = 0.548 and P Egger = 0.655; Supplementary data, Fig. S2a ). Sequential omission pattern showed no change by removing single study each time in sensitivity analyses (Supplementary data, Fig. S2b ).
Subgroup analysis of OS and TTP
To investigate the regional disparities of the difference between combination treatment and TACE monotherapy, subgroup analyses for OS and TTP were conducted by categorizing the included studies into non-Asian (USA/European countries) and Asian (Asia-Pacific countries) regions, respectively ( Table 5 ).
The pooled HR for OS was 0.57 (95% CI 0.45-0.72, P < 0.001) from the nine studies completed in Asian regions (I 2 = 62.8%, P = 0.006, random-effect model; Fig. 4a ), favoring the combination treatment. However, the combined HR for OS was 0.96 Figure 1 . PRISMA flow diagram of the process for identification of eligible studies. In the flow diagram, 2721 non-duplicated studies were initially identified, and 14 studies were finally included after abstract and full-text screening. (95% CI 0.73-1.20, P = 0.598) from the three studies in non-Asian countries (I 2 < 0.01%, P = 0.821, fixed-effect model; Fig. 4b ), showing no difference between treatments. Furthermore, we analyzed the combined HR for OS of RCTs in Asian countries (HR 0.92, 95% CI 0.65-1.32; Fig. 4c ). Unfortunately, there were only two studies meeting the requirements, one reported that HR for OS was 1.06 (95% CI 0.69-1.64) (29) , while the other one reported 0.68 (95% CI 0.36-1.30) (20) . As for non-Asian countries, the pooled HR of RCTs was 0.95 (95% CI 0.73-1.23; Fig. 4d ), in consistent with the above result of mixed research-type studies. The pooled HR for TTP in Asian countries (four studies) was 0.66 (95% CI 0.48-0.89; P = 0.006; Fig. 5a ) using a random-effect model due to significant heterogeneity (I 2 = 67.5%, P = 0.026). In contrast, the combined HR in non-Asian countries was 1.08 (95% CI 0.73-1.60) with a random-effect model (I 2 = 56.0%, P = 0.078; Fig. 5b) . Therefore, the combination therapy, comparing with TACE monotherapy, significantly reduced the risk of disease progression in Asian countries, but not in non-Asian countries. Similarly, we conducted a region-specific subgroup analysis of RCT studies for TTP, the pooled HR was 0.84 for Asian countries (95% CI 0.69-1.02; Fig. 5c ) and 1.08 for non-Asian countries (95% CI 0.73-1.60; same figure as Fig. 5b since all non-Asian studies were RCT studies).
Response to treatment
Six included studies provided data of ORR and DCR. The pooled RR for ORR was 1.11 (95% CI 0.58-2.13) using a random-effect model (I 2 = 87.4%, P < 0.001), showing no difference between combination and TACE monotherapy (Fig. 6a) . The funnel plots were symmetrical, indicating no significant publication bias, with P Begg = 1.000 and P Egger = 0.991 (Supplementary data, Fig. S3a ). However, we found that the combined RR for DCR was 1.30 (95% CI 1.00-1.69, z = 1.96, P = 0.05) in a random-effect model (I 2 = 84.7%, P < 0.001), indicating a better rate of disease control with the combination treatment of TACE and sorafenib comparing to TACE monotherapy (Fig. 6b ). Begg's funnel plots with P Begg = 0.060 and P Egger = 0.068 indicated no significant publication bias (Supplementary data, Fig. S3b ).
Adverse events
The reported adverse events associated with the treatment of sorafenib included HFSR, hematological events, diarrhea, hypertension, rash, fatigue and alopecia (16) (17) (18) 35) . A meta-analysis was conducted to evaluate the incidences of these adverse events. The pooled RRs were 7.03 for HFSR (95% CI 4.77-10.37; z = 9.85; P < 0.001), 2.75 for diarrhea (95% CI 1.74-4.35; z = 4.33; P < 0.001) and 2.58 for hypertension (95% CI 1.33-4.99; z = 2.81; P = 0.005), 2.87 for rash (95% CI 1.86-4.43; z = 4.76; P < 0.001) and 4.88 for alopecia (95% CI 1.67-14.13; z = 2.92; P = 0.004), indicating the combination treatment might result in significantly higher incidence comparing with the TACE monotherapy (Fig. S4) . However, the pooled RRs were 3.14 for hematological events (95% CI 0.99-10.01; z = 1.94; P = 0.053), and 1.25 for fatigue (95% CI 0.89-1.76; z = 1.29; P = 0.197), showing no significant difference in the risk of the adverse event incidence between the combination treatment and TACE monotherapy.
Discussions
The intriguing combination of TACE procedure and sorafenib has drawn numerous attention, with active research conducted. TACEinduced hypoxia exposure may stimulate angiogenesis and then lead to proliferation of the residual tumor cells (14) , which requires antiangiogenic agents such as sorafenib for synergetic tumor inhibition (12) . Over 20 studies are ongoing or have been completed (12) . Multiple RCTs have evaluated the feasibility of TACE and sorafenib combination for unresectable HCC, along with many cohort studies and case-control studies. The SPACE trial was the first global randomized, placebo-controlled trial combining TACE with a systemic anti-cancer agent (20) . The TACE 2 trial is the first randomized, placebo-controlled, phase 3 trial to explore the concurrent administration of sorafenib and DEB-TACE, with even more participants included than the SPACE trial. The long recruitment period during the TACE 2 trial provided sufficient follow-up window to acquire a detailed survival data (19) . However, the current evidence is still inconsistent and controversial. In the present meta-analysis including 13 studies and 2538 patients, we demonstrated that the TACE and sorafenib combination therapy significantly increased OS and might prolonged TTP, comparing with TACE alone. A more recent multicenter, phase 2, randomized trial (TACTICS) with 156 participants from Japan demonstrated an interim result that the combination therapy of TACE and sorafenib increased progression-free survival (HR = 0.59, 95% CI 0.41-0.87; P = 0.006) and TTP (HR = 0.56, 95% CI 0.38-0.83; P = 0.004) (36) , which partially support our analyzed results. Notably, the TACTICS trial also showed that sorafenib prolonged the time to untreatable progression, indicating that the HCC patients could benefit from the combination therapy for a longer treatment window of TACE.
In our meta-analysis, we synthesized RCT and non-RCT studies to get a larger sample size. The similar synthesis approach with a separate RCT/non-RCT subgroup analysis for drawing conclusions was also used in many previous meta-analyses (35, (37) (38) (39) . A previous meta-analysis which only included RCTs, in contrast to our results, showed a different outcome that TACE plus sorafenib only improved TTP but not OS (40) . Our further subgroup analysis indeed suggested an insignificant HR for OS in the RCT subgroup analysis, and a clear difference of HR for OS and TTP between RCT and non-RCT studies. The pooled analysis for non-RCT studies, rather than RCTs, was more likely to show a positive HR significance.
Unexpectedly, we also found a regional disparity in another subgroup analysis regarding the treatment efficacy between Asian and non-Asian regions. The pooled subgroup analysis of the nine studies conducted in Asian region, including both RCTs and non-RCT studies, indicated OS and TTP improvement with the combination therapy. In comparison, the three studies conducted in non-Asian regions showed no improvement in OS or TTP with the combination therapy. Therefore, the Asian patients with unresectable HCC, comparing with the non-Asian patients, might be more likely to benefit from the TACE and sorafenib combination therapy. In addition, the regional disparity might contribute to the difference between our study and the previous RCT-exclusive meta-analysis (40), since we included more studies with Asian participants. The superior results achieved in Asian regions might be caused by that more patients in the non-Asian region had a high number of early TACE discontinuations and a shorter treatment duration when compared with the Asian regions, according to the literature analysis in ESMO-ESDO guideline (41) .
As for Asian RCT studies, the pooled results, integrated with the special features of Asian HCCs and the solid evidence level of RCT studies, were particularly interesting. The results did not favor the combination therapy for OS improvement but showed a notably reduced risk, though without statistically significance, of disease progression with the combination therapy. However, only two Asian RCTs were included in the meta-analysis, with distinguished outcomes. The HR values in one report were 1.06 for OS (95% CI 0.69-1.64) and 0.87 for TTP (95% CI 0.70-1.09) (29) but were 0.68 for OS (95% CI 0.36-1.30) and 0.72 for TTP (95% CI 0.45-1.14) in the other report (20) . Specifically, Lencioni's study showed a greater improvement in OS and TTP in Asian patients over non-Asian patients, possibly because that non-Asian patients a shorter treatment course of TACE and sorafenib (20) . Furthermore, the global HCC BRIDGE study reported that the Chinese patients have a higher tumor load, with a mean tumor diameter of 6.7 cm, almost double in size that reported in the other countries (42) . The survival benefit could be modest with TACE monotherapy but might be better with the combination therapy in Chinese population (43) . Taking the results of Asian non-RCT studies into account, we should never ignore the importance of the regional disparities on the treatment efficacy of the combination therapy.
The ORR and the DCR are another two essential indicators for assessment of the therapeutic effect. Our findings showed that the combination therapy did not improve the ORR but might achieve better disease control, with evaluation data according to the Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST (mRECIST). The results indicated that the combination therapy might not reduce the tumor volume or alleviate disease but could help to maintain disease condition at a stable level.
Combination therapy might cause more adverse events due to toxicity of the TACE chemotherapeutics or systematic effect of sorafenib. In consistent with previous studies and reviews, our study showed much higher morbidity of adverse reaction in combination therapy group-most related with sorafenib treatment, including HFSR, diarrhea, hypertension, rash and alopecia. The incidence of fatigue or hematological events was similar between the combination therapy and the TACE-alone group. The increased rate of adverse events brought more challenge in clinical healthcare for the patients receiving the combination therapy. Fortunately, most reported adverse events are mild to moderate, suggesting a relatively bearable risk when balanced with the gained survival benefits. Furthermore, temporary dose reduction or even revocation of sorafenib is also an available strategy to reduce the side effects (31) . Most patients were able to recover from the adverse events and continued the combination therapy.
Regarding to the TACE methods, some included studies used doxorubicin-eluting beads while the others used gelatin sponge particles, polyvinyl alcohol particles or lipiodols. The 2012 EMSO-ESDO guidelines recommended TACE with selective administration with doxorubicin-eluting beads to minimize systemic side effects (41) . The 2018 EASL guidelines suggested that drug-eluting beads has shown similar benefit in comparison to conventional TACE (gelfoam-lipiodol particles) (3). Both major TACE methods, with similar therapeutic benefit according to the EASL guideline, were recommended, which might not cause significant heterogeneity. However, there was minor heterogeneity among different studies caused by several confounding factors, such as regimen dose, patient intolerance or operator experience.
There are some limitations in our systemic review and metaanalysis. First, we synthesized the data from RCTs and non-RCT studies, which might be controversial. The study results were drawn from the subgroup analysis we further conducted but were limited in efficacy due to the small number of available RCT literatures. Powerful RCTs performed in Asian regions or worldwide are still required. Second, highly heterogeneous characteristics in HCC patients resulted in varieties of accompanied pathological conditions such as cirrhosis, inducing the unbalanced distribution by these factors in our meta-analysis. The candidates for further studies on combination therapy should be carefully selected to reduce the bias. Finally, timing, sequence and duration of the combination treatment (12), which was not included in the current meta-analysis, need to be optimized.
In conclusion, our meta-analysis indicated that the combination therapy of TACE and sorafenib contributes to better survival outcome, delayed cancer progression and higher DCR in unresectable HCCs, especially in Asian studies rather than in non-Asian studies, when compared with TACE monotherapy. Further high-quality RCT studies performed in Asian regions are required to facilitate the optimal application of the combination therapy.
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